NAMSNewAmsterdam Pharma Co N.V.

Nasdaq newamsterdampharma.com


$ 21.74 $ -0.12 (-0.55 %)    

Friday, 10-May-2024 09:42:37 EDT
QQQ $ 441.99 $ -0.93 (-0.21 %)
DIA $ 395.44 $ 0.18 (0.05 %)
SPY $ 521.28 $ -0.24 (-0.05 %)
TLT $ 90.14 $ -0.17 (-0.19 %)
GLD $ 218.73 $ -1.05 (-0.48 %)
$ 21.86
$ 21.74
$ 0.00 x 0
$ 0.00 x 0
$ 21.74 - $ 21.74
$ 5.63 - $ 26.35
89,962
na
1.97B
$ 1.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 newamsterdam-pharma-q1-eps-106-vs-051-yoy

First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $...

 newamsterdam-pharma-to-present-new-analysis-from-the-phase-2-rose2-trial-evaluating-obicetrapib-in-combination-with-ezetimibe-at-2024-american-college-of-cardiology-congress

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin me...

 scotiabank-initiates-coverage-on-newamsterdam-pharma-with-sector-outperform-rating-announces-price-target-of-35

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and...

 scotiabank-initiates-coverage-on-newamsterdam-pharma-with-sector-outperform-rating-announces-price-target-of-35

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and...

 rbc-capital-maintains-outperform-on-newamsterdam-pharma-raises-price-target-to-31

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and raises the price targe...

 newamsterdam-pharma-reports-full-year-2023-eps-215-vs-119-yoy-revenue-141m-vs-1027m-yoy

Full Year 2023 Financial ResultsCash Position: As of December 31, 2023, NewAmsterdam recorded cash of $340.5 million, compared ...

 newamsterdam-pharma-prices-1753m-public-offering-of-ordinary-shares-and-pre-funded-warrants

NewAmsterdam Pharma announced the pricing of the previously announced underwritten public offering of (i) 4,488,159 of the Comp...

 newamsterdam-pharma-reveals-commencement-of-public-offering-of-ordinary-shares-and-pre-funded-warrants-no-terms-disclosed

In addition, the Company expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exc...

 why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

 world-acceptance-posts-upbeat-earnings-joins-kaman-spirit-airlines-and-other-big-stocks-moving-higher-on-friday

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporatio...

 guggenheim-initiates-coverage-on-newamsterdam-pharma-with-buy-rating-announces-price-target-of-30

Guggenheim analyst Debjit Chattopadhyay initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and announ...

 piper-sandler-initiates-coverage-on-newamsterdam-pharma-with-overweight-rating-announces-price-target-of-37

Piper Sandler analyst Yasmeen Rahimi initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Overweight rating and an...

 cholesterol-player-newamsterdam-pharmas-obicetrapib-is-a-potential-blockbuster-in-cardiovascular-market-bullish-analyst-says

Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor target...

 why-wd-40-shares-are-trading-higher-by-over-17-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected ...

 newamsterdam-pharma-announces-strategic-priorities-for-2024

-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase 3 BROOKLYN trial ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION